Barclays PLC Has $352,000 Position in Personalis, Inc. (NASDAQ:PSNL)

Barclays PLC increased its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 45.4% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 65,468 shares of the company’s stock after purchasing an additional 20,444 shares during the period. Barclays PLC’s holdings in Personalis were worth $352,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in shares of Personalis during the third quarter worth approximately $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in Personalis by 42.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock worth $81,000 after acquiring an additional 4,504 shares during the period. International Assets Investment Management LLC raised its stake in Personalis by 438.0% during the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after purchasing an additional 17,082 shares during the last quarter. Quantbot Technologies LP bought a new stake in Personalis in the 3rd quarter valued at $210,000. Finally, Semanteon Capital Management LP acquired a new stake in Personalis in the 3rd quarter worth $375,000. Institutional investors own 61.91% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on PSNL. Lake Street Capital upped their price objective on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Personalis in a report on Wednesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and set a $7.25 price objective on shares of Personalis in a report on Wednesday, January 8th.

Personalis Trading Up 2.3 %

NASDAQ PSNL opened at $4.89 on Monday. Personalis, Inc. has a 1-year low of $1.12 and a 1-year high of $7.20. The company has a market capitalization of $345.48 million, a price-to-earnings ratio of -2.91 and a beta of 1.75. The stock’s 50 day moving average is $4.72 and its two-hundred day moving average is $4.54.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $25.71 million during the quarter, compared to analyst estimates of $20.67 million. During the same period in the prior year, the firm earned ($0.51) EPS. On average, analysts predict that Personalis, Inc. will post -1.37 earnings per share for the current year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.